Pepti NAD+ Review: Vial Prices, Testing and Refill Terms

Pepti’s NAD+ injection page lists a 1,000 mg vial for $249 and a 2,000 mg option for $279, described as approximately four-week supplies. The Pepti Pen option is currently marked sold out. These are recurring refill prices, not a guaranteed calendar-month bill.¹³¹⁴

The more useful questions now are what the selected strength includes, when the next charge occurs, which pharmacy dispenses it and what the linked quality documents actually establish. A larger menu or a laboratory badge does not prove clinical benefit.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Embody

NAD+ injection or nasal spray, dosing protocol published

See Embody↗

The current price and specification

The standard vial is described as 10 mL at 100 mg/mL, totaling 1,000 mg. A separate selector offers 2,000 mg for $279, but the general formulation panel remains the standard 10 mL, 100 mg/mL example. Confirm the concentration, volume and directions for the selected strength rather than applying the standard panel to every option.¹³

The page also lists a 3 mL, 250 mg/mL pen cartridge containing 750 mg, while marking that format sold out. A displayed formulation is not confirmation that the format is available to order. We did not start an assessment or place an order.

Medication, physician review, refill management, shipping and messaging are described as included, with no separate membership fee. The same page offers optional in-depth at-home bloodwork for an additional $149. Its broader phrase “labs included” should not be read as meaning every panel is free. Ask which tests, if any, are required and included for your NAD+ prescription before adding optional monitoring.¹³

A 28-day refill is not a calendar month

The billing policy says medication renews on the cycle the supply lasts, normally every 28 days, with the exact date subject to the prescribed dose. It stores the payment method and renews until canceled. Thirteen 28-day fills cover 364 days: at $249 each, that is $3,237, rather than the $2,988 obtained by multiplying the price by twelve. That arithmetic describes thirteen fills at the listed price, not a guarantee of your individualized schedule.¹⁴

Dose changes can move the next charge date. The product page also says an approved strength increase is charged at the price difference and applied to the next fill. Confirm the next amount and date in the account after any change. For category comparisons, the NAD+ price index is useful only when supply duration and recurring charge are compared together.

The subscription page says the old three-supply prepay plan is no longer offered to new customers, while describing legacy arrangements for existing enrollees. Other paragraphs retain inconsistent language about whether prepaid bundles renew. A new customer should not infer a current bulk discount from those legacy terms; an existing customer should obtain their own renewal schedule in writing.¹⁴

Cancellation and refund qualifications

The medication subscription can be canceled through the account, under the relevant medication; support@hellopepti.com is also provided for assistance. Cancellation stops future charges and refills, but does not refund a supply already shipped. The policy permits eligible pauses of up to 90 days, followed by automatic resumption unless canceled.¹⁴¹⁶

Pepti's refund policy says payment is collected before provider review. If the provider declines treatment, it promises a full refund within 5–10 business days. Cancellation before pharmacy processing is also listed as a full-refund situation. Once medication ships, ordinary returns and refunds are excluded. Report damaged shipments or an incorrect product within seven days; the policy offers specified remedies for those situations and billing errors.¹⁵

The product's money-back-guarantee badge therefore should not be interpreted as an unconditional refund after trying the medication. Ask whether an order has entered pharmacy processing before assuming cancellation will recover the payment.

Pharmacy, clinician and state disclosures

The current pharmacy-fulfillment policy names Olympia Pharmacy among its partners and says the actual pharmacy depends on state, medication, licensing and availability. It says the dispensing pharmacy's name and address appear on the prescription paperwork and medication label. It does not guarantee Olympia will fill every NAD+ order.¹⁸

The product page identifies Dr. Gene Lee, MD as a physician reviewer and describes review by a licensed US physician. A physician named on a product page is not necessarily the clinician assigned to your care. The The Edit review discusses another provider's public clinical and pharmacy information.

The current state-availability page says 50 states, with explicit qualifications: treatments can vary by state, additional testing may be required, and individual eligibility is confirmed during assessment and checkout. Confirm NAD+-specific availability rather than equating national platform coverage with every product being available everywhere.¹⁷

What the posted testing does and does not show

Pepti now displays recent NAD+ lots with named laboratories, dates, sterility or endotoxin results and potency summaries. One displayed lot, 1629756, is described as 190 mg/mL measured against a 200 mg/mL label, or 95% of label. That is a different concentration from the standard 100 mg/mL product panel. A report for one preparation should not be treated as the report for every vial.¹³

The seller describes broader independent batch testing and a PCAB-accredited pharmacy network. We have not independently audited those programs or tested medication. Ask for the report matching the actual dispensed lot, its formulation, release testing, storage instructions and beyond-use date. Public test summaries address product quality; they do not establish that the treatment improves energy, cognition or longevity.

The capsule question remains a different evidence question

The current catalog does not confirm a purchasable nasal spray or capsule option. Ask support if you specifically want either format; do not assume an older advertised route or price is still available.

If an oral NAD+ capsule is offered, distinguish it from NR and NMN. Controlled human trials of NR and NMN support changes in blood NAD+ ²³⁴⁵. They do not validate swallowing an intact NAD+ dinucleotide, a different molecule of approximately 663 Daltons ⁶. Our route comparison explains why the shared word “oral” does not establish the same absorption or outcome.

Evidence for the current injection

Published subcutaneous pharmacokinetic evidence and established routine wellness benefits are limited. The 2019 IV experiment measured metabolites during a six-hour infusion ⁷, not outcomes from Pepti's home product. A small intramuscular hospital hearing-loss trial likewise cannot validate this prescription's routine energy or anti-aging claims. See the injection evidence review.

Nasal NAD+ experiments cited in this category include animal stroke and brain-injury models ⁸⁹, while nose-to-brain delivery remains a formulation-specific research problem ¹⁰. They do not establish a human clinical benefit for an unverified current Pepti nasal offer. Our nasal evidence page separates those findings. Even precursor trials that raise NAD+ have inconsistent downstream metabolic results ¹¹.

Who may find Pepti worth comparing?

Pepti publishes vial specifications, named pharmacy relationships, state limitations and lot-testing summaries. The buying tradeoffs are the roughly 28-day recurring charge, optional lab costs, concentration differences between formulations and the limits on refunds after processing or shipment.

Compare the current terms with Auren Rx, rather than comparing Pepti's current vial to an old $179 headline. If your aim is simply a better-supported way to raise a biomarker, is nicotinamide riboside worth it and NMN versus NR cover a separate purchase decision. The NAD+ rankings hub gives the wider context without turning product disclosure into evidence of a health benefit.